How to Apply Efinaconazole 10% Solution for Onychomycosis
Apply efinaconazole 10% solution once daily to the affected toenail(s) using the integrated flow-through brush applicator, ensuring complete coverage of the toenail surface, nail folds, nail bed, hyponychium, and undersurface of the nail plate for 48 weeks. 1
Application Technique
The FDA-approved application method is straightforward but requires thoroughness 1:
- Frequency: Once daily application
- Duration: 48 weeks of continuous treatment
- Coverage areas (all must be covered):
- Entire toenail surface
- Toenail folds (lateral and proximal)
- Nail bed (visible portion)
- Hyponychium (skin under the free edge)
- Undersurface of the nail plate (when accessible)
Key Application Points
Use the integrated flow-through brush applicator that comes with the medication—this delivery system is specifically designed to facilitate proper application and nail penetration 1. The formulation's low surface tension and poor water solubility enhance nail plate penetration compared to other topical antifungals 2.
No nail filing or debridement is required before application, which distinguishes efinaconazole from older topical agents like amorolfine that require removal of diseased nail areas by gentle filing 3. This represents a significant practical advantage in real-world use.
Treatment Context
Efinaconazole achieves mycological cure rates approaching 50% and complete cure rates of 15-25% depending on disease severity 3, 4. The drug is particularly effective in:
- Mild-to-moderate onychomycosis (≤80% nail involvement without lunula involvement) 3
- Early disease (<1 year duration) 5
- Female patients with lower BMI 2
- When only the large toenail is affected 2
Treat concomitant tinea pedis if present, as this improves outcomes 2.
Safety Profile
Systemic absorption is minimal with mean peak plasma concentrations of only 0.67 ng/mL in patients, resulting in negligible drug-drug interaction potential 6. Treatment-related adverse events are uncommon (6.0%) and primarily local: ingrown toenails (2.3%), application site dermatitis (2.2%), vesicles (1.6%), and pain (1.1%) 1.
For topical use only—not for oral, ophthalmic, or intravaginal use 1.